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Abstract: Trabectedin is a new marine-derived compound that binds the DNA minor groove 
and interacts with proteins of the DNA repair machinery. Trabectedin has shown promising 
single-agent activity in pretreated patients with soft tissue sarcoma, and ovarian and breast 
cancer, and combination with various other chemotherapeutic drugs seems feasible. Toxici-
ties are mainly hematologic and hepatic, with Grade 3–4 neutropenia and thrombocytopenia 
observed in approximately 50% and 20% of patients, respectively, and Grade 3–4 elevation of 
liver enzymes observed in 35%–50% of patients treated with trabectedin. The recently reported 
results of a large Phase III trial comparing pegylated liposomal doxorubicin (PLD) alone with a 
combination of PLD and trabectedin in patients with recurrent ovarian cancer showed improved 
progression-free survival with the combination of trabectedin and PLD, albeit at the price of 
increased toxicity. Current research focuses on the identification of predictive factors for patients 
treated with trabectedin, as well as the development of other combinations.
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Introduction
Epithelial ovarian cancer is the leading cause of death from gynecologic cancers in 
Western countries.1,2 Most patients present with advanced disease (ie, Stage III and IV), 
and are managed with surgical resection followed by platinum-based chemotherapy.3 
During the past decade, advances in chemotherapy have resulted in improved survival 
and in more effective treatment of relapsed disease. However, five-year overall survival 
remains relatively low, at around 30%.4
The most important prognostic factors at primary diagnosis are International Fed-
eration of Gynecologists and Obstetricians (FIGO) stage and complete resection of 
disease (microscopic residual disease following primary surgery). The time point of 
relapse following the completion of chemotherapy defines the category of platinum 
sensitivity, ie, the longer the interval, the longer the duration of response likely to be 
achieved by platinum retreatment. Patients whose disease responds to first-line therapy 
but relapses $12 months after completion of initial platinum-based therapy are con-
sidered to have platinum-sensitive disease. Patients who relapse 6–12 months after 
primary therapy have intermediate or partial platinum-sensitive disease. Patients who 
relapse shortly (,six months) after the completion of primary therapy, are considered 
to have platinum-resistant disease. Patients who relapse during primary therapy are 
considered to have platinum-refractory disease.
Chemotherapy retreatment is an important aspect in the overall management 
of patients with platinum-sensitive relapse of recurrent ovarian cancer. Platinum is Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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the backbone of chemotherapy for patients with advanced   
ovarian cancer, and carboplatin and paclitaxel have emerged 
as standard in the first-line setting. This combination is also 
regarded as a valid option for rechallenge in patients with 
platinum-sensitive recurrent ovarian cancer. A pooled analy-
sis of three Phase III trials from the Arbeitsgemeinschaft 
Gynaëkologische Onkologie Studiengruppe Ovarialkar-
zinom and International Collaborative Ovarian Neoplasm 
collaborators demonstrated significant improvements in 
progression-free survival and overall survival in patients 
with platinum-sensitive recurrent ovarian cancer treated 
with platinum-paclitaxel versus conventional, mainly single-
agent, platinum-based therapies.5 However, rechallenge with 
carboplatin and paclitaxel has been limited by the risk of 
cumulative peripheral neuropathy. Other carboplatin-based 
combinations, such as gemcitabine and carboplatin, have 
been explored with the aim of improving both efficacy 
and tolerability. Carboplatin and gemcitabine significantly 
improved progression-free survival versus carboplatin alone 
in a Phase III trial (hazards ratio [HR] 0.72, P = 0.0031).6 
Overall survival, however, was not significantly improved 
(HR 0.96, P = 0.735), although the trial was not powered to 
detect a survival difference. Grade 3–4 hematologic toxici-
ties were significantly more frequent in the combination arm. 
More recently, Pujade-Lauraine et al reported a Phase III 
trial comparing carboplatin and paclitaxel with carboplatin 
and pegylated liposomal doxorubicin (PLD) in patients with 
ovarian carcinoma relapsing more than six months after 
first- or second-line platinum- and taxane-based therapy.7 In 
this trial, the largest in recurrent ovarian cancer, treatment 
with carboplatin and PLD was associated with improved 
progression-free survival (11.3 versus 9.4 months, P = 0.005) 
and a favorable safety profile.
Treatment options for patients with partial platinum-
sensitive disease (six months # platinum-free interval 
, 12 months) include carboplatin-based doublets (either 
with paclitaxel or gemcitabine), which achieve progression-
free survival durations of approximately eight months,8 
and PLD.9 In this subset of patients, PLD was shown to 
be superior to topotecan in terms of both progression-free 
survival and overall survival,10 although it has never been 
compared “head to head” with a platinum doublet. Overall 
survival in patients with partial platinum-sensitive disease 
recurrence is approximately 13–15 months. An emerging 
strategy in these patients is to “artificially” increase the 
platinum-free interval by using a nonplatinum-containing 
regimen upon relapse, with the aim of reversing platinum 
resistance.11
In patients with platinum-resistant or refractory recurrent 
ovarian cancer, treatment options are limited, and this patient 
subgroup has a poor prognosis. Agents that can be considered 
include PLD, topotecan, gemcitabine, paclitaxel, oral etopo-
side, and vinorelbine. Because the reported response rate for 
each of these drugs is in the 10%–20% range in patients with 
platinum-resistant disease, the choice is often driven by the 
side effect profile and the convenience of administration.12 
Topotecan and PLD have been more extensively studied in 
this setting, and seem to provide some benefit in progression-
free survival, although rarely associated with an improvement 
in overall survival.
Trabectedin: a minor groove 
alkylator
Trabectedin (ET743, Yondelis®; PharmaMar, Madrid, Spain), 
a tetrahydroisoquinoline alkaloid, is a natural product 
derived from the marine tunicate Ecteinascidia turbinate. 
Trabectedin (ET743) binds to the minor groove of DNA and 
alkylates guanine at the N2 position, whereas most alkylat-
ing agents bind guanine at position N7 or O6 in the major 
groove. Binding of trabectedin has been shown to be DNA 
sequence-specific, with guanine-cytosine rich triplets more 
frequently bound.13 Covalent binding of trabectedin induces 
DNA bending towards the major groove and a widening of 
the DNA minor groove.14 Modification of the DNA confor-
mation leads to inhibition of activated transcription, while 
constitutive transcription seems unaffected.15
ET743 has shown potent antitumor activity in pre-
clinical studies both in vitro and in vivo in several solid 
tumors, including ovarian and breast cancer, melanoma, and 
sarcoma.16,17 These preclinical data have been confirmed in 
several Phase II trials in soft tissue sarcoma, and breast and 
ovarian carcinoma. Trabectedin is approved in the European 
Union and several other countries for the treatment of 
relapsed soft tissue sarcoma which has progressed despite 
previous treatment with anthracyclines and ifosfamide, or 
in those who are unable to receive these agents. It is also 
approved in the European Union in combination with PLD 
for the treatment of platinum-sensitive recurrent ovarian 
cancer. In addition, trabectedin holds orphan drug status 
for the treatment of advanced recurrent soft tissue sarcoma 
in the US, Switzerland, and Korea, and for the treatment of 
advanced recurrent ovarian cancer in the US and Switzerland. 
Trabectedin is under development for prostate cancer, breast 
cancer, and pediatric soft tissue sarcoma.
Several reports have underlined the importance of 
  nucleotide-excision repair in the cytotoxicity of ET743, Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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and more precisely the cell killing ability of this drug has 
been linked to transcription-coupled nucleotide-excision 
repair.13,14,18 The DNA bending induced by the binding of tra-
bectedin to the minor groove is detected by the transcription-
coupled nucleotide-excision repair machinery, which in the 
repair process makes single-strand breaks on each side of the 
lesion.13 These breaks are then made irreversible by the DNA-
protein crosslinking capacities of trabectedin.19 Recently 
Herrero et al18 suggested a slightly different model based on 
their observations in the yeast model, Schizosaccharomyces 
pompe. In this model, cells deficient for Rad13 (the yeast 
equivalent to human XPG, an endonuclease of the nucleotide-
excision repair system), were resistant to trabectedin, while 
those with an inactive Rad51 (a protein of the homologous 
recombination repair pathway, involved in the repair of 
double-strand breaks) were more sensitive to trabectedin 
than wild-type cells. Based on these observations, Herrero 
et al suggested the following sequence: trabectedin binds 
covalently to the DNA minor groove, the resulting adduct 
is recognized by the nucleotide-excision repair machinery, 
and then the recruited Rad13 (XPG) protein binds to DNA 
and interacts with the minor groove-bound drug by means 
of an arginine residue located in the COOH terminus. Other 
proteins of the nucleotide-excision repair machinery trying 
to repair the damage are then hijacked, forming larger, more 
toxic complexes. Lastly, during the S phase, the aforemen-
tioned complexes give rise to double-strand DNA breaks, 
explaining the sensitivity of cells deficient for homologous 
recombination repair pathway proteins (eg, Rad51).18
Single-agent trabectedin  
in advanced ovarian carcinoma
Three Phase II studies have investigated the activity of 
trabectedin in patients with recurrent advanced ovarian 
cancer (Tables 1 and 2). Based on preclinical data showing 
that trabectedin was active in xenograft models with low 
sensitivity to cisplatin or paclitaxel, Sessa et al20 reported 
the results of a Phase II study of trabectedin in patients with 
ovarian cancer failing platinum- and taxane-based therapy. 
Fifty-nine patients were enrolled and stratified according to 
platinum sensitivity, ie, 30 patients with platinum-resistant 
disease (no change after at least four cycles of platinum or 
taxane, progressive disease after two cycles, or relapse within 
an interval of less than six months after discontinuation 
of chemotherapy) and 29 patients with platinum-sensitive 
disease (relapse after a progression-free interval of $six 
months after completion of platinum-based chemotherapy). 
Twenty-two (37%) patients had received at least two prior 
Table 1 Summary of efficacy of trabectedin as a single agent in 
relapsed ovarian cancer
Study PFI  
(months)
n CR PR ORR Median PFS   
(months)
Sessa  
et al20
,6 months
$6 months
30
29
0
1 (3%)
2 (7%)
9 (31%)
7%
34%
NR
NR
Krasner  
et al21
,6 months
6–12 months
$12 months
81
43
23
0
1 (2%)
3 (13%)
5 (6%)
9 (22%)
5 (22%)
6%
24%
35%
2.0
4.0
5.1
Del  
Campo  
et al22
,6 months
6–12 months
$12 months
7
48
52
0
NR
NR
1
NR
NR
14.3%
29.9%
48.1%
NR
5.6
10.8
Abbreviations:  PFi,  platinum-free  interval;  CR,  complete  response;  PR,  partial 
responses; ORR, overall response rate; NR, not reported.
lines of treatment. Trabectedin was administered as a three-
hour infusion every three weeks, initially given at the dose of 
1650 µg/m² based on the recommended Phase II dose found 
in Phase I trials. The dose in this study was subsequently 
decreased to 1500 µg/m², and then to 1300 µg/m², because 
of toxicity (essentially liver toxicity). Systemic antiemetic 
prophylaxis with intravenous 5-hydroxytryptamine-3 
antagonists and 10 mg of dexamethasone intravenously 
was mandatory, and patients took 4 mg of dexamethasone 
bid for prophylaxis against liver toxicity. Fifty-one patients 
were assessable according to RECIST (Response Evaluation 
Criteria In Solid Tumors) criteria. The overall response rate 
in the 23 assessable patients with platinum-sensitive disease 
was 43.5%, (one complete response lasting 8.7 months and 
nine partial responses) and an additional nine patients had 
stable disease. Median time to progression for patients who 
achieved a partial response was 7.9 months. In the platinum-
resistant stratum, the overall response rate was 7%, and two 
of 28 patients achieved a partial response lasting 4.0 and 
4.6 months. Stable disease was achieved by eight additional 
patients (28.6%). At the higher dose level of 1650 µg/m² 
Grade 4 elevation of liver transaminases, asthenia, and nausea 
and vomiting were seen in 83%, 82%, and 50% of patients. 
At the 1300 µg/m² dose level, treatment was well tolerated 
with a transient increase in transaminases and Grade 3–4 
neutropenia. Two patients (3%) in this study experienced 
febrile neutropenia (one at the 1650 µg/m² dose level and 
the other at the 1300 µg/m² dose level).20
The results of the second Phase II trial of trabectedin in 
patients with ovarian carcinoma were reported by Krasner 
et al.21 This study enrolled 147 patients who had received 
no more than two prior platinum-containing regimens. Tra-
bectedin was administered as a three-hour infusion weekly 
for three weeks of a four-week cycle at 580 µg/m², after 
premedication by 10 mg of intravenous dexamethasone. Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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Table 2 Summary of the most commonly encountered Grade 3–4 side effects in single-agent trials of trabectedin in patients with 
ovarian cancer
Study Schedule Infusion  
time  
(hours)
n AST ALT Bilirubin Neutro-  
penia
Thrombo-  
cytopenia
Fatigue Nausea  
vomiting
Sessa et al20 1650 µg/m²/3 wks 3 6 6 (100%)a - 0 NA NA NA NA
1500 µg/m²/3 wks 3 12 10 (84%)a - 0 NA NA NA NA
1300 µg/m²/3 wks 3 41 31 (75%)a - 0 17 (41%) 3 (7%) 3 (7%) 2 (5%)
Krasner  
et al21
580 µg/m²/wk  
3/4 wks
3 147 4 (3%) 18 (12%) 0 12 (8%) 4 (3%) 8 (5%) 8 (5%)
Del Campo 
et al22
1500 µg/m²/3 wks 24 54 19 (35%) 30 (56%) 0 29 (54%) 4 (8%) 8 (15%) 2 (4%)
1300 µg/m²/3 wks 3 53 10 (19%) 31 (58%) 1 (2%) 20 (38%) 5 (10%) 4 (8%) 3 (6%)
Note: aPooled data for AST/ALT elevation. 
Abbreviations: AST, aspartate transaminase; ALT, alanine transaminase; wk, week.
One hundred and forty-one patients were evaluable by 
RECIST criteria, ie, 62 in the platinum-sensitive cohort 
(defined as relapse after a disease-free interval $ six months 
from the end of the last platinum-based chemotherapy) and 
79 in the platinum-resistant cohort (defined as disease pro-
gression , six months from the end of the last platinum-based 
treatment). The overall response rate (by RECIST) was 29% 
in the platinum-sensitive cohort (four complete responses 
and 14 partial responses), and the median progression-free 
survival was 5.1 months. In the platinum-resistant cohort, 
the overall response rate was 6.3% (five partial responses) 
and the median progression-free survival was two months. 
Toxicity was much more manageable than in the European 
Phase II study, as a result of the weekly schedule and the 
lower initial dose intensity delivered. Nausea, vomiting, and 
fatigue were seen in 50%–60% of patients. The most common 
Grade 3–4 toxicities were elevated alanine transaminases 
(11%), neutropenia (6%), and nausea, vomiting, and fatigue 
(5% each).
Del Campo et al reported on a randomized Phase II study 
comparing two schedules of trabectedin, ie, 1500 µg/m² over 
24 hours every three weeks (arm A) and 1300 µg/m² over 
three hours every three weeks (arm B), the primary endpoint 
being the response rate.22 Patients received the recommended 
antiemetic prophylaxis with setron and dexamethasone. One 
hundred and eight patients were randomized between the two 
arms, and 107 received treatment. The intent to treat analysis 
showed comparable response rates between the two arms 
(38.9 in arm A, 35.8 in arm B, P = 0.8422). Likewise, the pro-
gression-free survival was similar in both arms (6.2 months 
in arm A, 6.8 months in arm B, P = 0.3127) suggesting that 
the two schedules have similar activity. The most common 
adverse events were nausea, vomiting, and fatigue, in most 
cases Grade 1 or 2. Hematologic toxicity was manageable, 
and mostly consisted of neutropenia and thrombocytopenia. 
Febrile neutropenia was seen in five patients (5%), and two 
patients died of possible drug-related adverse events.
McMeekin et al reported a pooled analysis of three 
Phase II studies, including 294 patients, in which three dif-
ferent schedules of administration were compared, one with 
1300 µg/m² over three hours, one with 1500 µg/m² over 
24 hours, both every three weeks, and one with 580 µg/m² 
weekly, for three weeks of a 28-day cycle.23 However, no 
significant differences in efficacy were seen between the 
two every three-week schedules, as was seen in patients with 
sarcoma.24 These two schedules were significantly superior to 
the weekly schedule, with a better response rate (33% versus 
16%, P # 0.0001) and longer median time to progression 
(5.8 months versus 2.8 months, P = 0.0001).
Overall, these Phase II studies show that trabectedin 
has single-agent activity in patients with platinum-sensitive 
relapsed ovarian carcinoma, with a manageable toxicity pro-
file. The activity of trabectedin in platinum-resistant disease 
seems more disappointing (Table 1), with reported response 
rates lower than those reported for other agents currently 
available, such as PLD, topotecan,9 or gemcitabine.25,26
Trabectedin-based combinations
Several Phase I trials of trabectedin-based combinations 
have been reported, and showed that trabectedin could be 
safely combined with doxorubicin,27,28 PLD,29 gemcitabine,30 
taxanes,31,32 and capecitabine.33
A recently published article has reported on a Phase I trial 
investigating the combination of trabectedin and cisplatin.28 
There is a strong preclinical rationale for this combination 
based on the mechanisms of action of both drugs which target 
different pathways of DNA repair (nucleotide excision repair for 
trabectedin and homologous recombination for cisplatin) and Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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on synergistic activity against human tumor xenografts. Sessa 
et al conducted a Phase I trial of trabectedin and cisplatin, both 
given on days 1 and 8 of a 21-day cycle.28 Trabectedin was given 
as a three-hour infusion, starting at 300 µg/m² (with 100 µg/m² 
increments), and cisplatin at a fixed dose of 40 mg/m². Persistent 
neutropenia was the most common dose-limiting toxicity in 
this study, and several patients had not recovered from Grade 
3 neutropenia by day 35. The recommended Phase II dose 
of trabectedin was 500 µg/m² on days 1 and 8 in pretreated 
patients and 600 µg/m² on days 1 and 8 in treatment-naive 
patients (combined with cisplatin 40 mg/m² on days 1 and 8). 
Although antitumor activity was seen with this combination, 
the results were lower than expected, especially in patients 
with ovarian carcinoma, and the response rate was comparable 
with that of single-agent trabectedin (with limitations due to 
the small sample size of n = 13). One of the hypotheses raised 
by the authors to explain these deceiving results is that the tra-
bectedin dose intensity was insufficient due to prolonged dose 
delays.28 Development of a three-week schedule was therefore 
suggested. However, it is noteworthy that these findings are in 
line with a previous Phase I trial of a combination of trabectedin 
and carboplatin where hematologic toxicity precluded a dose 
increase of trabectedin beyond 800 µg/m² every three weeks 
and carboplatin beyond an area under the concentration-time 
curve (AUC) of 4 mg/mL/min.34
Other interesting candidates for combination with tra-
bectedin in patients with ovarian cancer include gemcitabine, 
PLD, and the taxanes. Data on these combinations are sum-
marized in Table 3.
Messersmith et al conducted a Phase I trial exploring the 
combination of trabectedin and gemcitabine.30 Both drugs 
were administered on days 1, 8, and 15 of a 28-day cycle. 
Two dose levels were planned for gemcitabine (800 and 
1000 mg/m²) and five were planned for trabectedin (300, 
400, 475, 535, and 580 µg/m²). Fifteen patients were enrolled, 
of whom five had sarcomas, three had non-small-cell lung 
cancer, two had colorectal cancer, and two had renal cell 
carcinoma. All patients but one were pretreated with che-
motherapy and 12 patients had received at least two prior 
regimens. This study was terminated early because of an 
unacceptable frequency of dose adjustments due to hepatic 
toxicity. Patients received a median of two (range 1–10) 
treatment cycles. The dose-escalation scheme was stopped at 
level 3 (trabectedin 400 µg/m² and gemcitabine 1000 mg/m²) 
where four of six patients required dose hold/cycle delay. 
Overall cycle delays and dose holds were required in 11 (of 
15) patients, in most cases during the two first cycles and 
most often related to liver toxicity. Dose reductions were 
required for trabectedin in four patients and gemcitabine 
in six patients. Dose-limiting toxicity was defined as any 
of the following during the first cycle: Grade 4 neutropenia 
(absolute neutrophil count , 500/mL) for . five days; febrile 
neutropenia (absolute neutrophil count , 500/mL with fever 
[body temperature 38.5°C] or sepsis); thrombocytopenia 
(platelets , 25,000/mL); any Grade 3 nonhematologic 
toxicity (except nausea/vomiting and Grade 3 transaminitis 
lasting , one week); or delay of continuation of therapy 
. three weeks. Dose reductions were not considered as dose-
limiting toxicities. No dose-limiting toxicities were seen in 
any of the cohorts. The most frequently reported Grade 3 or 
4 adverse event was alanine transaminase increase (33%). 
Although the study was terminated without reaching the 
maximum tolerated dose, toxicity appeared potentially man-
ageable without evidence of a significant pharmacokinetic 
interaction with this combination. No objective response 
was noted, but two patients in this study had stable disease 
for more than six months. The recommended dose for 
future   trials investigating this combination was trabectedin 
400 µg/m² combined with gemcitabine 1000 mg/m² weekly 
for three weeks every four weeks.
von Mehren et al conducted a Phase I study to assess the 
maximum tolerated dose, safety, and potential pharmacoki-
netic interactions of trabectedin in combination with PLD.29 
Thirty-six patients with normal liver function, prior doxoru-
bicin exposure , 250 mg/m², and normal cardiac function 
were enrolled. A broad range of advanced malignancies was 
  represented, the most common being sarcoma (n = 16), ovarian 
cancer (n = 4), and pancreatic cancer (n = 2). Twenty-seven 
patients (75%) were pretreated with chemotherapy, with a 
median of three prior regimens. PLD was administered at 
the dose of 30 mg/m² with a one-hour infusion, and   followed 
immediately by one of six trabectedin doses (400, 600, 750, 
900, 1100, and 1300 µg/m²) infused over three hours and 
repeated every 21 days. All patients received dexamethasone 
4 mg/day orally on the day before chemotherapy and on days 
2 and 3 of each cycle, as well as 20 mg intravenously on 
day 1. Dose-limiting toxicity was defined as the following 
during cycle 1: an absolute neutrophil count , 500/mL for 
.five days or with fever or sepsis; platelet count , 25,000/
mL; any Grade 3 or 4 nonhematologic toxicity (except for 
nausea/vomiting despite appropriate antiemetic treatment 
or Grade 3 transaminase elevations lasting , one week); or 
a delay of therapy for .three weeks. The median number 
of cycles was four. The maximum tolerated dose was PLD 
30 mg/m² + trabectedin 1100 µg/m². Dose-limiting toxicities 
occurred in two patients in the 1300 µg/m² cohort during Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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Table 3 Summary of data on trabectedin-based combination of potential interest in ovarian cancer
Combination Reference Schedule Recommended 
Phase II dose
Dose-limiting  
toxicity
Efficacy  
in ovarian  
cancer patients
Comments
Trabectedin
Cisplatin
27 Days 1 and 8 
every 21 days
Days 1 and 8 
every 21 days
500–600 µg/m²
40 mg/m²
Prolonged  
neutropenia
Four of 13 
patients (31%) 
with OC  
had a PR
Deceiving  
efficacy-wise  
and toxic
Trabectedin
Gemcitabine
29 Days 1, 8 
and 15 every 
28 days
Days 1, 8 
and 15 every 
28 days
400 µg/m²
1000 mg/m²
None NR
Trabectedin
PLD
28 Day 1 every 
21 days
Day 1 every 
21 days
1100 µg/m²
30 mg/m²
Grade 3–4  
transaminitis  
lasting . 7 days
One patient with 
PPC had a PR  
and 2 of 4 patients 
with OC has SD
A subsequent  
phase iii trial in  
patients with ROC  
showed improved  
RR and PFS compared   
with PLD alone
Trabectedin
Docetaxel
30 Day 1 every 
21 days
Day 1 every 
21 days
1100 µg/m²
60 mg/m²
Grade 4 neutropenia  
and/or febrile  
neutropenia before  
primary prophylaxis  
with filgrastim.  
Grade 3 fatigue.
NR A subsequent phase ii 
trial in patients with  
ROC showed a RR,  
PFS and OS of 30%,  
4.4 months and  
12.5 months 
respectively
Trabectedin
 
Paclitaxel
31 Day 2 every 
14 days
Day 1 every 
14 days
650 µg/m²
 
120 mg/m²
Grade 4 neutropenia  
lasting 5 days or  
more, dose  
delays beyond 8 days
One patient  
with OC has  
PD (no response)
Abbreviations: PLD, pegylated liposomal doxorubicin; OC, ovarian cancer; ROC, relapsed ovarian cancer; PR, partial response; NR, not reported; RR, response rate; PFS, 
progression-free survival; OS, overall survival; PD, progressive disease; SD, stable disease.
cycle 1, consisting of Grade 3 or 4 transaminase elevations 
lasting . seven days. The most frequent Grade 3 or 4 drug-
related events were alanine transaminase elevations (31%) 
and neutropenia (31%). Transaminase elevations resolved 
without specific intervention and were successfully man-
aged with dose reductions. Post-treatment liver biopsies 
were carried out in eight patients who had elevations in liver 
function tests, and nonalcoholic steatohepatitis was present 
in seven of eight biopsies. Six patients had an asymptom-
atic reduction of left ventricular ejection fraction of $20% 
versus baseline. Only one of these six patients had received 
a prior anthracycline-based regimen, although all six had a 
cumulative exposure to anthracyclines of $300 mg/m2 (range 
365–690 mg/m2) when noted to have a change in the left 
ventricular ejection fraction. Finally, one complete response 
and five partial responses (overall response rate 16.7%) were 
seen and 14 patients had stable disease. The majority of 
responses occurred in the 1100 µg/m² and the 1300 µg/m² 
cohorts. Overall, these data show that trabectedin combined 
with PLD is feasible with encouraging activity. The regimen 
comprising PLD 30 mg/m² plus trabectedin 1100 µg/m² was 
selected for a Phase III trial comparing PLD alone with PLD 
plus trabectedin in patients with advanced ovarian cancer 
failing one prior platinum-based regimen.
von Mehren et al reported the results of a Phase I trial 
of docetaxel 60 mg/m² combined with trabectedin as a 
three-hour infusion on day one of a three-week cycle.31 Six 
dose levels (400 µg/m² through to 1300 µg/m²) and two 
independent cohorts, ie, “restricted” (#one prior regimen) 
and “unrestricted” (no limits as to the number of previous 
regimens) were planned. Thirty-four patients were enrolled, 
10 of whom had sarcoma. Five patients developed dose-
limiting toxicity at the 600 µg/m² dose level, ie, Grade IV 
neutropenia and/or febrile neutropenia requiring institution 
of prophylactic filgrastim. After institution of filgrastim, 
only one dose-limiting toxicity (fatigue) was observed at the 
1300 µg/m² dose level. The most frequent Grade 1–2 adverse 
events were fatigue (68%), nausea (58%), and neutropenia 
(53%). Preliminary data suggest activity for this combination 
in patients with advanced cancer, with one patient achieving Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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a complete response and 17 maintaining prolonged stable 
disease. A subsequent Phase II trial in patients with recurrent 
ovarian cancer used doses of 60 mg/m² for docetaxel and 
1100 µg/m² of trabectedin given every three weeks. In the 
preliminary report of this trial, the response rate was 30%, 
and the median progression-free survival and overall survival 
were 4.4 months and 12.5 months, respectively.35
In their Phase I study, Chu et al administered escalating 
doses of paclitaxel (80–120 mg/m2) over one hour on day 1 
and trabectedin (525–775 µg/m2) as a three-hour infusion on 
day 2 every two weeks.32 Twenty-nine patients were enrolled, 
including 23 patients with soft tissue sarcoma, and 27 patients 
were evaluable. Two doses were planned for paclitaxel 
(80 mg/m² or 120 mg/m²) and four doses for trabectedin (525, 
580, 650, or 775 µg/m²), and five schedules were tested. There 
were four dose-limiting toxicities due to neutropenia delaying 
therapy for more than one week, two of which occurred on 
paclitaxel 120 mg/m² + trabectedin 775 µg/m². Therefore, the 
recommended dose was paclitaxel 120 mg/m² + trabectedin 
650 µg/m². The most common toxicities were neutropenia 
(24%), nausea (51%), vomiting (24%), transaminitis (23%), 
myalgia (24%), and alopecia (20%). Evidence of antitumor 
activity and clinical benefit was seen, with one patient who 
had a primitive neuroectodermal tumor showing an ongoing 
complete response at 19+ months, one patient with breast 
cancer (prior paclitaxel failure) having an unconfirmed partial 
response, and eight patients having stable disease for more 
than three months.
Trabectedin–PLD combination  
in relapsed ovarian carcinoma
Based on the activity of both PLD and trabectedin in patients 
with relapsed ovarian carcinoma, together with a favorable 
safety profile described in Phase I investigations, a Phase III 
trial comparing a combination of PLD and trabectedin with 
PLD alone in patients with recurrent ovarian cancer was initi-
ated. Six hundred and seventy-two patients progressing after 
initial response to first-line platinum-based therapy and with 
measurable disease were randomized to a combination of PLD 
30 mg/m2 over 60 minutes and trabectedin 1100 µg/m2 over 
three hours every 21 days (PLD + T, with 10 mg intravenous 
dexamethasone 30 minutes prior to trabectedin infusion) 
or standard PLD 50 mg/m2 once every four weeks. Patients 
experiencing disease progression during platinum-based front-
line therapy were excluded.36 Progression-free survival was 
the primary study endpoint and was assessed by independent 
radiologic review. Baseline characteristics were comparable 
between arms, ie, median age was 57 years, 421 patients 
(63%) had platinum-sensitive disease (platinum-free interval 
for more than six months). The median number of cycles was 
five for PLD and six for PLD + T. Median progression-free 
survival for the combination arm was 7.3 months (95% CI 
5.9–7.9) and 5.8 months (95% CI 5.5–7.1) for single-agent PLD 
(HR = 0.79, P = 0.019). For patients with platinum-sensitive 
disease (platinum-free interval more than six months), the 
median progression-free survival was 9.2 months (95% CI 
7.4–11.1) for the combination arm versus 7.5 months (95% 
CI 7.0–9.2) for PLD alone (HR 0.73, P = 0.017). Objective 
response rate for all patients was 28% versus 19% (P = 0.008) 
and 35% versus 23% (P = 0.0042) for patients with platinum-
sensitive disease. In the platinum-resistant subgroup, there was 
no benefit in progression-free survival (4.0 versus 3.7 months 
for PLD + T and PLD, respectively) nor in response rate 
(overall response rate 16% versus 15% for PLD + T and PLD, 
respectively). There was no overall survival difference between 
the two arms, ie, 20.5 months for PLD + T versus 19.4 months 
for PLD alone (HR 0.85, P = 0.15). However, follow-up was 
insufficient at the time of reporting. Sixteen percent of patients 
in the combination arm and 10% in the single-agent PLD arm 
discontinued treatment because of adverse events. Grade 3 
and Grade 4 adverse events included neutropenia (63% versus 
22%), elevated alanine transaminase (31% versus 1%), and 
hand-foot syndrome (4% versus 20%) for PLD + T versus PLD 
alone, respectively. On the basis of these results, the authors 
concluded the superior efficacy the PLD + T combination, 
which also demonstrates competitive efficacy compared with 
previously described platinum-based combinations in patients 
with platinum-sensitive relapsed ovarian cancer.
Despite these conclusions, the FDA denied approval for 
the combination of trabectedin and PLD in patients with 
relapsed ovarian carcinoma. One of the reasons was that the 
FDA panel felt that the six-week benefit in progression-free 
survival shown in this trial did not justify approval of the 
drug. Progression-free survival has not been proven to be a 
valid surrogate for overall survival in patients with relapsed 
ovarian cancer, and the increment itself is relatively low given 
the added toxicity. Furthermore, although PLD is an option in 
patients with relapsed platinum-sensitive disease, platinum-
based therapy may be regarded as the preferred treatment 
in this patient subgroup. Therefore, given the fact that this 
study included a majority of patients with platinum-sensitive 
disease, the validity of the comparator may be questioned. 
Another point of discussion is the lack of benefit in patients 
with platinum-resistant disease, although this is in line with 
previous data showing that trabectedin has little efficacy in 
this patient subgroup.20–22 Finally, there was an increase in Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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the rate of nonfatal congestive heart failure-related events 
in the trabectedin group (six events for PLD + T versus one 
for PLD alone).36
Interestingly, a subgroup analysis of this study, reported at 
the 2010 ASCO meeting, suggested that patients with partial 
platinum-sensitive disease may benefit the most from this 
combination.37 Indeed, 214 patients in this trial had partial 
platinum-sensitive disease. In this subgroup, the median pro-
gression-free survival was 7.4 months for patients treated in 
the combination arm (T + PLD) versus 5.5 months for patients 
treated with PLD alone. Furthermore, this benefit translated 
into an overall survival advantage of 3.5 months (20.7 versus 
17.2, P = 0.009). Two comments can be made on these results. 
First, because there was no crossover in this study, one cannot 
rule out that giving sequential single-agent PLD followed by 
trabectedin at progression may be as or even more effective 
than the combination. Second, we still need more follow-up 
to assess overall survival in the whole cohort.
In another subgroup analysis of this trial, investigators 
sought to identify predictive factors for patients receiving 
trabectedin.38 This study focused on proteins of the nucle-
otide-excision repair and homologous recombination repair 
pathways because these pathways are important for trabect-
edin activity in vitro. The markers studies included ERCC1, 
XPG (both part of the nucleotide-excision repair machinery), 
and BRCA1 (homologous recombination repair pathway), 
and their expression was studied using real-time polymerase 
chain reaction on prechemotherapy tumor blocks. Patients 
with low BRCA1 mRNA levels had significantly longer 
overall survival (P = 0.0297) and progression-free survival 
(P = 0.0427) than those with high BRCA1 levels, thereby 
confirming the prognostic value of BRCA1 expression in 
patients with ovarian carcinoma.39 A trend (P = 0.0765) for 
longer overall survival (but not progression-free survival) was 
found for patients with high ERCC1 expression levels. No 
significant differences in progression-free survival or overall 
survival emerged for low or high XPD expression levels. No 
significant differences in progression-free survival or overall 
survival were observed with the combined expression of 
BRCA1 and ERCC1. Caveats of these analyses include low 
numbers of patients with samples available and/or of adequate 
quality (139 of 672 patients, 20%), prior platinum-based 
therapy in all patients (and 80% prior taxanes) which might 
have modified the tumor RNA expression levels.
Other new agents in ovarian cancer
Several agents are currently in development in ovarian can-
cer, and can be grouped into three classes, ie, antiangiogenic 
agents, cell surface-targeted agents, and poly-adenosine 
triphosphate (ADP) ribose polymerase inhibitor.
Bevacizumab has shown promising results in several 
Phase II trials, and the Gynecologic Oncology Group 
GOG218 Phase III trial was recently reported at the 
2010 ASCO meeting, showing improved progression-
free survival for patients receiving first-line carboplatin-
  paclitaxel and bevacizumab, with bevacizumab maintenance 
therapy. Interestingly, the progression-free survival in the 
chemotherapy and bevacizumab without maintenance beva-
cizumab arm was not significantly different from that of the 
standard arm (carboplatin-paclitaxel alone). This trial there-
fore raises the question as to whether bevacizumab should 
be given as a maintenance therapy only, or whether it really 
needs to be combined in the initial chemotherapy regimen. 
Furthermore, the improvement in progression-free survival 
is limited, especially given that maintenance bevacizumab 
was given every three weeks for 16 cycles (approximately 
11 months), and there is currently no overall survival 
advantage for patients receiving bevacizumab (insufficient 
follow-up). Therefore, it seems reasonable to wait for the 
overall survival data to mature, as well as data from other 
randomized trials (ICON7 trial), before we incorporate 
bevacizumab as part of standard practice.
Several antiangiogenic tyrosine kinase inhibitors (TKIs) 
are currently under active investigation in the treatment of 
advanced ovarian cancer. Cediranib, an oral TKI of vascular 
endothelial growth factor receptor (VEGFR)-1, VEGFR-2, 
VEGFR-3, and c-kit, showed interesting single-agent activity 
in a recently published Phase II trial in patients with relapsed 
ovarian carcinoma.40 BIBF1120, a TKI targeting the VEGF, 
the platelet-derived growth factor, and the fibroblast growth 
factor receptor, has shown promising activity as maintenance 
therapy in a randomized Phase II trial.41 Pazopanib, another 
TKI targeting the VEGF and platelet-derived growth factor 
receptor, has shown some activity in patients with biochemi-
cal relapse of ovarian cancer.42 Both of these agents are cur-
rently being evaluated in Phase III trials, either in combination 
(BIBF1120) or as maintenance therapy (pazopanib).4
Cell surface targets in ovarian carcinoma include CA-125 
and epithelial cell adhesion molecule. However, the current 
role of the relevant agents (oregomovab, abagomovab, and 
catumaxomab) in the management of patients w  ith advanced 
ovarian cancer remains unclear, owing to the lack of a 
  specific trial.
The most recent class of drug developed for patients with 
advanced ovarian cancer includes the poly-(ADP-ribose)-
polymerase (PARP) inhibitors. This class of   compound Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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targets PARPs, which are DNA repair enzymes. Preclini-
cal experiments have shown synthetic lethality in cells 
deficient in BRCA 1 or BCRA 2.43,44 A single-agent Phase 
I trial showed interesting activity in tumors from BRCA 
1 or BRCA 2 mutation carriers, with a favorable toxicity 
profile.45 Gelmon et al reported a Phase II trial in triple-
negative breast and high-grade serous ovarian carcinoma 
demonstrating significant activity of single-agent olaparib 
in non-BRCA-mutated patients with advanced high-grade 
ovarian carcinoma.46 However, an analysis of the expansion 
cohort of the Phase I study of olaparib in BRCA mutation 
carriers showed a correlation between response and dura-
tion of the platinum-free interval, suggesting that PARPs 
may not be as active in patients with platinum-resistant 
disease.47 PARP inhibitors can also be combined with 
standard chemotherapy, most notably with DNA-damaging 
agents, with which they are most likely to be synergistic. 
Only Phase I trials have been reported to date for patients 
with ovarian carcinoma.
Conclusion
Trabectedin, a new marine-derived compound, has shown 
interesting activity in patients with platinum-sensitive 
relapsed ovarian carcinoma. However, several agents are 
currently approved for this indication, including paclitaxel, 
gemcitabine, and PLD. The standard of care in this setting 
remains the combination of carboplatin and paclitaxel, and 
a recent Phase III study showed improved progression-free 
survival and overall survival with weekly paclitaxel coupled 
with carboplatin for patients with platinum-sensitive recur-
rent ovarian cancer.48
When combined with PLD, trabectedin improved pro-
gression-free survival over PLD alone, although no overall 
survival advantage has yet emerged.36 Furthermore, the 
progression-free survival benefit is numerically small (six 
weeks) and comes at the price of a significant increase in 
toxicity, although somewhat different from those seen with 
platinum or platinum-taxane regimens which are standard for 
this indication. Another drawback of this study is that single-
agent PLD cannot be considered as standard in patients with 
platinum-sensitive relapsed ovarian cancer. Based on these 
observations, the use of trabectedin in the management of 
patients with platinum-sensitive disease cannot be clearly 
defined, and more studies are needed. However, recent data 
indicate that patients with partial platinum-sensitive dis-
ease benefit from the combination of trabectedin and PLD 
compared with PLD alone, with superior progression-free 
survival and overall survival for the combination.37
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